FDA Labeling Restriction Quickly Reflected in Oncology Practice
TUESDAY, Oct. 29, 2019 -- The June 2018 U.S. Food and Drug Administration label restriction on first-line immunotherapy for advanced bladder cancer was associated with a decrease in immunotherapy use and an increase in chemotherapy use, according to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Immunotherapy | Pharmaceuticals